

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/059,506
		Filing Date	01/29/2002
		First Named Inventor	Kelly, Kathleen
		Group Art Unit	1042
		Examiner Name	A. M. Harris, Ph.D.
Sheet 1 of 2	Attorney Docket Number	015280-263110US	

10/059506
01/29/02

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	AA					
	AB					

FOREIGN PATENT DOCUMENTS								
Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	B1	WO	98/06838		Van Lier, et al.	19-02-1998		
	B2							

Examiner Signature	<i>A. M. Harris</i>	Date Considered	12/31/2003
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SF 1311303 v1

Please type a plus sign (+) inside this box ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/059,506
		Filing Date	01/29/2002
		First Named Inventor	Kelly, Kathleen
		Group Art Unit	1642
		Examiner Name	AM Harris, Ph.D.
Sheet 2 of 2	Attorney Docket Number	015280-263110US	

J0957 U.S. PTO
 10/059506
 01/29/02

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
anh	A1	Hamann, J. et al., "Expression Cloning and Chromosomal Mapping of the Leukocyte Activation Antigen CD97, a New Seven-Span Transmembrane Molecule of the Secretin Receptor Superfamily with an Unusual Extracellular Domain," <i>J. of Immunology</i> , 155(4):1942-1950 (1995).	
↓	A2	Hamann, J. et al., "Structure of the Human CD97 Gene: Exon Shuffling has Generated a new Type of Seven-Span Transmembrane Molecule Related to the Secretin Receptor Superfamily," <i>Genomics</i> , 32(1):144-147 (1996).	
↓	A3	Hamann, J. et al., "The Seven-Span Transmembrane Receptor CD97 has a Cellular Ligand (CD55, DAF)," <i>J. of Experimental Medicine</i> , 184(3):1185-1189 (1996).	
anh	A4	Hamann, J. et al., "Expression Cloning of the Human CD97 Antigen," <i>J. of Cellular Biochemistry Supplement</i> 0(21A):72 (1995).	
anh	A5	Gray, J. et al., "CD97 is a Processed, Seven-Transmembrane, heterodimeric Receptor Associated with Inflammation," <i>J. of Immunology</i> 157(12):5438-5447 (1996).	
anh	A6	Eichler, W., et al., "Expression characteristics of the human CD97 antigen," <i>Tissue Antigens</i> 50(5):429-438 (1997).	
anh	A7	Aust, G., et al., "CD97: A Dedifferentiation Marker in Human Thyroid Carcinomas," <i>Cancer Research</i> 57(9):1798-1806 (1997).	
↓	A8	Amino acid database, Accession #P48960, updated 09/15/2003; created 02/01/1996.	
↓	A9	Amino acid database, Accession #137225/P26706, updated 17/15/1998; created 08/01/1992.	
↓	A10	Rojanasakul, Y., "Antisense oligonucleotide therapeutics: drug delivery and targeting," <i>Advanced Drug Delivery Reviews</i> 18:115-313 (1996).	

Examiner Signature	AM Harris	Date Considered	12/31/2003, 1/5/2003
--------------------	-----------	-----------------	----------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SF 1311303 v1